Based on the analysis of Equillium's profitability, liquidity, and operating efficiency, Equillium is not in a good financial situation at this time. It has a very high odds of going through financial crisis in August. At this time, Equillium's Long Term Debt is relatively stable compared to the past year. As of 07/27/2024, Cash And Short Term Investments is likely to grow to about 63 M, while Property Plant And Equipment Net is likely to drop slightly above 682.7 K. Key indicators impacting Equillium's financial strength include:
Investors should never underestimate Equillium's ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Equillium's cash flow, debt, and profitability to make informed and accurate decisions about investing in Equillium.
Net Income
(14 Million)
Equillium
Select Account or Indicator
Market Cap
Enterprise Value
Ptb Ratio
Book Value Per Share
Free Cash Flow Yield
Invested Capital
Operating Cash Flow Per Share
Capex To Depreciation
Pb Ratio
Free Cash Flow Per Share
Roic
Net Income Per Share
Payables Turnover
Cash Per Share
Pocfratio
Interest Coverage
Capex To Operating Cash Flow
Pfcf Ratio
Days Payables Outstanding
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Graham Number
Shareholders Equity Per Share
Debt To Equity
Capex Per Share
Graham Net Net
Interest Debt Per Share
Debt To Assets
Enterprise Value Over E B I T D A
Short Term Coverage Ratios
Price Earnings Ratio
Price Book Value Ratio
Price Earnings To Growth Ratio
Days Of Payables Outstanding
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Ebt Per Ebit
Effective Tax Rate
Company Equity Multiplier
Long Term Debt To Capitalization
Total Debt To Capitalization
Return On Capital Employed
Debt Equity Ratio
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Cash Ratio
Cash Flow Coverage Ratios
Price To Book Ratio
Capital Expenditure Coverage Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Debt Ratio
Cash Flow To Debt Ratio
Return On Assets
Price Fair Value
Return On Equity
Sale Purchase Of Stock
Investments
Change In Cash
Net Borrowings
Total Cashflows From Investing Activities
Other Cashflows From Financing Activities
Depreciation
Capital Expenditures
Total Cash From Operating Activities
Change To Operating Activities
Net Income
Total Cash From Financing Activities
End Period Cash Flow
Change To Netincome
Change To Liabilities
Stock Based Compensation
Free Cash Flow
Change In Working Capital
Begin Period Cash Flow
Other Non Cash Items
Cash And Cash Equivalents Changes
Cash Flows Other Operating
Issuance Of Capital Stock
Total Assets
Short Long Term Debt Total
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Other Liab
Net Tangible Assets
Property Plant And Equipment Net
Net Debt
Retained Earnings
Accounts Payable
Cash
Non Current Assets Total
Non Currrent Assets Other
Long Term Debt
Cash And Short Term Investments
Common Stock Total Equity
Common Stock Shares Outstanding
Short Term Investments
Long Term Debt Total
Liabilities And Stockholders Equity
Non Current Liabilities Total
Capital Surpluse
Other Current Assets
Other Stockholder Equity
Total Liab
Net Invested Capital
Property Plant And Equipment Gross
Short Long Term Debt
Total Current Assets
Accumulated Other Comprehensive Income
Non Current Liabilities Other
Net Working Capital
Short Term Debt
Common Stock
Property Plant Equipment
Other Assets
Retained Earnings Total Equity
Capital Stock
Capital Lease Obligations
Interest Income
Interest Expense
Selling General Administrative
Gross Profit
Operating Income
Net Income From Continuing Ops
Ebit
Research Development
Cost Of Revenue
Total Operating Expenses
Income Before Tax
Total Other Income Expense Net
Net Income Applicable To Common Shares
Income Tax Expense
Net Interest Income
Depreciation And Amortization
Other Operating Expenses
Ebitda
Reconciled Depreciation
Non Operating Income Net Other
Probability Of Bankruptcy
Understanding current and past Equillium Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Equillium's financial statements are interrelated, with each one affecting the others. For example, an increase in Equillium's assets may result in an increase in income on the income statement.
The data published in Equillium's official financial statements typically reflect Equillium's business processes, product offerings, services, and other fundamental events. However, there are additional fundamental indicators that are easier to understand and visualize along the underlying realities that are driving Equillium's quantitative information. For example, before you start analyzing numbers published by Equillium accountants, it's essential to understand Equillium's liquidity, profitability, and earnings quality within the context of the Biotechnology space in which it operates.
Please note, the imprecision that can be found in Equillium's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Equillium. Check Equillium's Beneish M Score to see the likelihood of Equillium's management manipulating its earnings.
Equillium Stock Summary
Equillium competes with Lyra Therapeutics, Hookipa Pharma, Jasper Therapeutics, SAB Biotherapeutics, and Anebulo Pharmaceuticals. Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California. Equillium operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 45 people.
Foreign Associate
Canada
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
Equillium's financial ratios allow both analysts and investors to convert raw data from Equillium's financial statements into concise, actionable information that can be used to evaluate the performance of Equillium over time and compare it to other companies across industries.
The reason investors look at the income statement is to determine what Equillium's earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
Comparative valuation techniques use various fundamental indicators to help in determining Equillium's current stock value. Our valuation model uses many indicators to compare Equillium value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Equillium competition to find correlations between indicators driving Equillium's intrinsic value. More Info.
Equillium is rated below average in return on equity category among its peers. It is rated # 2 in return on asset category among its peers . At this time, Equillium's Return On Equity is relatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Equillium by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
Equillium Systematic Risk
Equillium's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Equillium volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Beta measures systematic risk based on how returns on Equillium correlated with the market. If Beta is less than 0 Equillium generally moves in the opposite direction as compared to the market. If Equillium Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Equillium is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Equillium is generally in the same direction as the market. If Beta > 1 Equillium moves generally in the same direction as, but more than the movement of the benchmark.
Equillium Thematic Clasifications
Equillium is part of Pharmaceutical Products investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. USA Equities from Pharmaceutical Products industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions
This theme covers USA Equities from Pharmaceutical Products industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions. Get More Thematic Ideas
Today, most investors in Equillium Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Equillium's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Equillium growth as a starting point in their analysis.
Along with financial statement analysis, the daily predictive indicators of Equillium help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Equillium. We use our internally-developed statistical techniques to arrive at the intrinsic value of Equillium based on widely used predictive technical indicators. In general, we focus on analyzing Equillium Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Equillium's daily price indicators and compare them against related drivers.
When running Equillium's price analysis, check to measure Equillium's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Equillium is operating at the current time. Most of Equillium's value examination focuses on studying past and present price action to predict the probability of Equillium's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Equillium's price. Additionally, you may evaluate how the addition of Equillium to your portfolios can decrease your overall portfolio volatility.